OCULAR THERAPEUTIX, INC 8K

Ocular Therapeutix reported Q2 2026 results, confirmed a Q4 2026 NDA submission plan for AXPAXLI in wet AMD with FDA alignment and 505(b)(2) review, detailed Phase 3 program updates and reduced treatment-burden data, and indicated its $598.6 million cash balance should fund operations into 2028 as it prepares for a potential 2027 launch.

On August 3, 2026, Ocular Therapeutix, Inc. reported its second quarter 2026 financial results and provided a comprehensive business update centered on its lead retinal candidate AXPAXLI (OTX-TKI), confirming FDA alignment from a May 2026 Type C meeting that allows submission of a New Drug Application for wet AMD in Q4 2026 under the Section 505(b)(2) pathway based primarily on SOL-1 Week 52 efficacy and safety data plus interim SOL-R safety data and confirmatory evidence, outlining protocol amendments to the SOL-R and HELIOS-3 Phase 3 trials to enhance label potential and durability positioning, describing progress in the SOL-X long‑term extension study, highlighting post‑hoc SOL-1 analyses showing up to an estimated 72% reduction in injection treatment burden versus on‑label aflibercept (2 mg) dosing, and disclosing a $78.8 million quarterly net loss, flat product revenues of $13.5 million, and a cash balance of $598.6 million expected to fund operations into 2028 as the company accelerates commercial readiness ahead of a potential 2027 launch of AXPAXLI if approved.

Filing Facts

CIK

1393434

Ticker

OCUL

Form

8K

Source Type

fda

Accession

0001104659-26-089443

Alert Tier

7